SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Xilio Therapeutics to Report Initial XTX501 Phase 1 Data in Q4 2027

Valid market news retained in the public archive without immediate LiveCast distribution.

XLO

Story updates

11:37:10 AM UTC
SquawkNews
Xilio Therapeutics dosed the first patient in a Phase 1/2 trial of XTX501 in metastatic NSCLC after prior anti-PD(L)-1 therapy and expects initial Phase 1 data in Q4 2027.Material DetailsContext by AI AnalystThis is an early-stage clinical milestone for a new I-O bispecific, moving XTX501 from prec…

Related stories